A Comparison Between Child-Pugh and Albumin-Bilirubin Scores

A Comparison Between Child-Pugh and Albumin-Bilirubin Scores in Patients With Spontaneous Rupture of Hepatocellular Carcinoma: A Retrospective Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03534843

Enrollment

230

Registered

2018-05-23

Start date

2005-01-01

Completion date

2018-01-01

Last updated

2018-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatic Impairment, Hepatocellular Carcinoma, Rupture Liver, Rupture, Spontaneous

Keywords

Spontaneous rupture, survival, hepatocellular carcinoma, Child-Pugh, Albumin-bilirubin

Brief summary

To compare Child-Pugh and Albumin-Bilirubin scores in patients with spontaneous rupture of hepatocellular carcinoma

Detailed description

To compare Child-Pugh and Albumin-Bilirubin scores in patients with spontaneous rupture of hepatocellular carcinoma. And to determine which is better in predicting long-term survival and short-term survival.

Interventions

PROCEDURELiver resection

Liver resection was comprised of single or multiple liver resections aiming to excise all macroscopic tumors.

OTHERTranscatheter arterial embolization

Transcatheter arterial embolization or transcatheter arterial chemoembolization can localize the bleeding point and provide interventional embolization.

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

15 Years to 76 Years

Healthy volunteers

Inclusion criteria

* Be diagnosed as hepatocellular carcinoma pathologically; had a tumor rupture confirmed by Intraperitoneal exploration or clinical signs and symptoms in combination with imaging examination.

Exclusion criteria

* Be diagnosed as not hepatocellular carcinoma pathologically；had repeated transcatheter arterial chemoembolization(TACE) or a long history (more than 1 year) of cancer treatment; loss of follow up or without complete data.

Design outcomes

Primary

Measure	Time frame	Description
Overall survival of all patients	5 years	Overall survival of all patients among different Child-Pugh and albumin-bilirubin scores

Secondary

Measure	Time frame	Description
Short-term mortality of all patients	Ninety days	Ninety-day mortality of all patients among different Child-Pugh and albumin-bilirubin scores
Short-term mortality of surgical subgroup	Ninety days	Ninety-day mortality of the surgical subgroup among different Child-Pugh and albumin-bilirubin scores
Short-term mortality of non-surgical subgroup	Ninety days	Ninety-day mortality of the non-surgical subgroup among different Child-Pugh and albumin-bilirubin scores

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 4, 2026